Acute Radiation Syndrome Medical Countermeasures-Amendment, 80552-80554 [2022-28437]
Download as PDF
80552
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
Page 9 ~·Michael Lynch. RocheMolecularSystems, Inc.
V. Duration. of Authorization
'this EUA will be effective untifthe dedatatfon that circumstances existjustifying 1he
authorization oftheemergencyuse ofinvitto diagnostics fotd~tection and/or: diagnosis of
infectionwith.the•·111onlreyp<>x·virui;,:inc~udinginvitro·diagnostics thatdetectlltld/ordiagno~e
infectionwith non,variolaOrthopat-virus, is terminated under Section 564(b)(2) ofthe. Act or
the EUAisrevoked underSectibn 564(g) ofthe Act.
Sincerely;c
Namandje N. Bumpus, Ph;D.
Chief Scientist
Food and Drug Adrn:inistratiori.
Enclosure.
[FR Doc. 2022–28460 Filed 12–29–22; 8:45 am]
BILLING CODE 4164–01–C
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Acute Radiation Syndrome Medical
Countermeasures—Amendment
ACTION:
Declaration amendment.
The Secretary is amending the
Declaration issued in the Federal
Register of October 10, 2008, and as
amended and republished January 1,
2016, pursuant to the Public Health
Service Act, to extend the effective time
period of the Republished Declaration,
as amended.
DATES: This amendment of the January
1, 2016, Republished Declaration is
effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L.
Paige Ezernack, Administration for
Strategic Preparedness and Response,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201; 202–260–
0365, paige.ezernack@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services (the Secretary) to issue a
Declaration to provide liability
immunity to certain individuals and
entities (Covered Persons) against any
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
claim of loss caused by, arising out of,
relating to, or resulting from the
administration or use of medical
countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, division C, section 2. It amended
the Public Health Service (PHS) Act,
adding section 319F–3, which addresses
liability immunity, and section 319F–4,
which creates a compensation program.
These sections are codified in the U.S.
Code as 42 U.S.C. 247d–6d and 42
U.S.C. 247d–6e, respectively. Section
319F–3 of the PHS Act has been
amended by the Pandemic and AllHazards Preparedness Reauthorization
Act (PAHPRA), Public Law 113–5,
enacted on March 13, 2013, and the
Coronavirus Aid, Relief, and Economic
Security (CARES) Act, Public Law 116–
136, enacted on March 27, 2020, to
expand Covered Countermeasures under
the PREP Act.
The Secretary is now amending the
Republished Declaration to extend the
time period for which liability
immunity is in effect for all of the
Covered Countermeasures to December
31, 2027.
Renewal of the PREP Act declaration
for acute radiation exposure is requested
due to the continued national security
threat posed. A nuclear attack or other
exposure to ionizing radiation would
present the United States with major
challenges in our ability to protect the
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
public. PREP Act coverage of
countermeasures is critical to the
engagement with potential product
sponsors to include those
countermeasures that would be used in
a response, such as blood products.
Extension of the PREP Act declaration
including covered countermeasures for
acute radiation exposure will be critical
to United States’ preparedness for
events involving ionizing radiation.
Unless otherwise noted, all statutory
citations below are to the U.S. Code.
Republished Declaration
Declaration, as Amended, for Public
Readiness and Emergency Preparedness
Act Coverage for Acute Radiation
Syndrome Medical Countermeasures
This Declaration amends the January
1, 2016, Republished Declaration under
the PREP Act. To the extent any term of
the prior Declaration is inconsistent
with any provision of this Republished
Declaration, the terms of this
Republished Declaration are controlling.
I. Determination of Public Health
Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d–6d(b)(1)
I have determined that there is a
credible risk that an unintentional
radioactive release, a deliberate
detonation of a nuclear device, or other
radiological or nuclear incident that
could result in population exposures to
radiation and resulting acute radiation
syndrome and/or delayed effects of
acute radiation exposure may in the
future constitute a public health
emergency.
E:\FR\FM\30DEN1.SGM
30DEN1
EN30DE22.029
Dated: December 27, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
II. Factors Considered
VI. Covered Countermeasures
42 U.S.C. 247d–6d(b)(6)
42 U.S.C. 247d–6b(c)(1)(B), 42 U.S.C.
247d–6d(i)(1) and (7)
I have considered the desirability of
encouraging the design, development,
clinical testing, or investigation,
manufacture, labeling, distribution,
formulation, packaging, marketing,
promotion, sale, purchase, donation,
dispensing, prescribing, administration,
licensing, and use of the Covered
Countermeasures.
I recommend, under the conditions
stated in this Declaration, the
manufacture, testing, development,
distribution, administration, or use of
the Covered Countermeasures.
Covered Countermeasures are any
antimicrobial (antibiotic, antifungal,
antiviral); any other drug; any biologic;
or any diagnostic or other device
administered to identify, prevent or
treat acute radiation syndrome and its
associated clinical manifestations, or
delayed effects of acute radiation
exposure or adverse events from such
countermeasures.
Covered Countermeasures must be
‘‘qualified pandemic or epidemic
products,’’ or ‘‘security
countermeasures,’’ or drugs, biological
products, or devices authorized for
investigational or emergency use, as
those terms are defined in the PREP Act,
the FD&C Act, and the PHS Act.
IV. Liability Immunity
VII. Limitations on Distribution
42 U.S.C. 247d–6d(a), 247d–6d(b)(1)
42 U.S.C. 247d–6d(a)(5) and (b)(2)(E)
Liability immunity as prescribed in
the PREP Act and conditions stated in
this Declaration is in effect for the
Recommended Activities described in
section III.
I have determined that liability
immunity is afforded to Covered
Persons only for Recommended
Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts,
cooperative agreements, grants, other
transactions, interagency agreements,
memoranda of understanding, or other
Federal agreements, or activities directly
conducted by the Federal Government.
or
(b) Activities authorized in
accordance with the public health and
medical response of the Authority
Having Jurisdiction to prescribe,
administer, deliver, distribute or
dispense the Covered Countermeasures
following a declaration of an emergency.
i. The Authority Having Jurisdiction
means the public agency or its delegate
that has legal responsibility and
authority for responding to an incident,
based on political or geographical (e.g.,
city, county, tribal, state, or Federal
boundary lines) or functional (e.g., law
enforcement, public health) range or
sphere of authority.
ii. A declaration of emergency means
any declaration by any authorized local,
regional, state, or Federal official of an
emergency specific to events that
indicate an immediate need to
administer and use the Covered
Countermeasures, with the exception of
a Federal Declaration in support of an
EUA under section 564 of the FD&C Act
unless such Declaration specifies
otherwise.
I have also determined that for
governmental program planners only,
liability immunity is afforded only to
the extent such program planners obtain
III. Recommended Activities
42 U.S.C. 247d–6d(b)(1)
V. Covered Persons
khammond on DSKJM1Z7X2PROD with NOTICES
42 U.S.C. 247d–6d(i)(2), (3), (4), (6),
(8)(A) and (B)
Covered Persons who are afforded
liability immunity under this
Declaration are manufacturers,
distributors, program planners,
‘‘qualified persons,’’ and their officials,
agents, and employees, as those terms
are defined in the PREP Act, and the
United States.
In addition, I have determined that
the following additional persons are
qualified persons: (a) Any person
authorized in accordance with the
public health and medical emergency
response of the Authority Having
Jurisdiction, as described in section VII
below, to prescribe, administer, deliver,
distribute or dispense the Covered
Countermeasures, and their officials,
agents, employees, contractors and
volunteers, following a declaration of an
emergency; (b) Any person authorized
to prescribe, administer, or dispense the
Covered Countermeasures or who is
otherwise authorized to perform an
activity under an Emergency Use
Authorization (EUA) in accordance with
section 564 of the Federal Food, Drug,
and Cosmetic (FD&C) Act, and; (c) Any
person authorized to prescribe,
administer, or dispense Covered
Countermeasures in accordance with
section 564A of the FD&C Act.
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
80553
Covered Countermeasures through
voluntary means, such as (1) donation;
(2) commercial sale; (3) deployment of
Covered Countermeasures from federal
stockpiles; or (4) deployment of
donated, purchased, or otherwise
voluntarily obtained Covered
Countermeasures from state, local, or
private stockpiles.
VIII. Category of Disease, Health
Condition, or Threat
42 U.S.C. 247d–6d(b)(2)(A)
The category of disease, health
condition, or threat for which I
recommend the administration or use of
the Covered Countermeasures is acute
radiation syndrome or delayed effects of
acute radiation exposure resulting from
an unintentional radioactive release, a
deliberate detonation of a nuclear
device, or other radiological or nuclear
incident.
IX. Administration of Covered
Countermeasures
42 U.S.C. 247d–6d(a)(2)(B)
Administration of the Covered
Countermeasure means physical
provision of the countermeasures to
recipients, or activities and decisions
directly relating to public and private
delivery, distribution and dispensing of
the countermeasures to recipients,
management and operation of
countermeasure programs, or
management and operation of locations
for purpose of distributing and
dispensing countermeasures.
X. Population
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(C)
The populations of individuals
include any individual who uses or is
administered the Covered
Countermeasures in accordance with
this Declaration.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered to this
population; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered to this population, or the
program planner or qualified person
reasonably could have believed the
recipient was in this population.
XI. Geographic Area
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(D)
Liability immunity is afforded for the
administration or use of a Covered
E:\FR\FM\30DEN1.SGM
30DEN1
80554
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
Countermeasure without geographic
limitation.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered in these
geographic areas; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered in these geographic areas,
or the program planner or qualified
person reasonably could have believed
the recipient was in these geographic
areas.
XII. Effective Time Period
42 U.S.C. 247d–6d(b)(2)(B)
Liability immunity for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction extends through
December 31, 2027.
Liability immunity for Covered
Countermeasures administered and
used in accordance with the public
health and medical response of the
Authority Having Jurisdiction begins
with a Declaration and lasts through (1)
the final day the emergency Declaration
is in effect or (2) December 31, 2027,
whichever occurs first.
XIII. Additional Time Period of
Coverage
khammond on DSKJM1Z7X2PROD with NOTICES
42 U.S.C. 247d–6d(b)(3)(B) and (C)
I have determined that an additional
twelve (12) months of liability
protection is reasonable to allow for the
manufacturer(s) to arrange for
disposition of the Covered
Countermeasure, including return of the
Covered Countermeasures to the
manufacturer, and for Covered Persons
to take other appropriate actions to limit
the administration or use of the Covered
Countermeasures.
Covered Countermeasures obtained
for the Strategic National Stockpile
(SNS) during the effective period of this
Declaration for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction are covered through
the date of administration or use
pursuant to a distribution or release
from the SNS.
XIV. Countermeasures Injury
Compensation Program
42 U.S.C. 247d–6e
The PREP Act authorizes the
Countermeasures Injury Compensation
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a serious
physical covered injury as the direct
result of the administration or use of the
Covered Countermeasures and/or
benefits to certain survivors of
individuals who die as a direct result of
the administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical, and scientific evidence in
order for the individual to be considered
for compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov/cicp/.
XV. Amendments
42 U.S.C. 247d–6d(b)(4)
The October 10, 2008, Declaration
Under the PREP Act for Acute Radiation
Syndrome Medical Countermeasures
was first published on October 17, 2008,
and amended and republished on
January 1, 2016. This is the second
amendment to the Declaration.
Further amendments to this
Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d–6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022–28437 Filed 12–29–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Workshops on Computational and Analytical
Research Methods.
Date: January 30, 2023.
Time: 1:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, National Institute
on Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Translating Research to Practice to
end the Overdose Crisis.
Date: February 10, 2023.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 594–9460,
Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: December 27, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28449 Filed 12–29–22; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 87, Number 250 (Friday, December 30, 2022)]
[Notices]
[Pages 80552-80554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28437]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Acute Radiation Syndrome Medical Countermeasures--Amendment
ACTION: Declaration amendment.
-----------------------------------------------------------------------
SUMMARY: The Secretary is amending the Declaration issued in the
Federal Register of October 10, 2008, and as amended and republished
January 1, 2016, pursuant to the Public Health Service Act, to extend
the effective time period of the Republished Declaration, as amended.
DATES: This amendment of the January 1, 2016, Republished Declaration
is effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L. Paige Ezernack, Administration for
Strategic Preparedness and Response, Department of Health and Human
Services, 200 Independence Avenue SW, Washington, DC 20201; 202-260-
0365, [email protected].
SUPPLEMENTARY INFORMATION: The Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes the Secretary of Health and
Human Services (the Secretary) to issue a Declaration to provide
liability immunity to certain individuals and entities (Covered
Persons) against any claim of loss caused by, arising out of, relating
to, or resulting from the administration or use of medical
countermeasures (Covered Countermeasures), except for claims that meet
the PREP Act's definition of willful misconduct. The Secretary may,
through publication in the Federal Register, amend any portion of a
Declaration.
The PREP Act was enacted on December 30, 2005, as Public Law 109-
148, division C, section 2. It amended the Public Health Service (PHS)
Act, adding section 319F-3, which addresses liability immunity, and
section 319F-4, which creates a compensation program. These sections
are codified in the U.S. Code as 42 U.S.C. 247d-6d and 42 U.S.C. 247d-
6e, respectively. Section 319F-3 of the PHS Act has been amended by the
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA),
Public Law 113-5, enacted on March 13, 2013, and the Coronavirus Aid,
Relief, and Economic Security (CARES) Act, Public Law 116-136, enacted
on March 27, 2020, to expand Covered Countermeasures under the PREP
Act.
The Secretary is now amending the Republished Declaration to extend
the time period for which liability immunity is in effect for all of
the Covered Countermeasures to December 31, 2027.
Renewal of the PREP Act declaration for acute radiation exposure is
requested due to the continued national security threat posed. A
nuclear attack or other exposure to ionizing radiation would present
the United States with major challenges in our ability to protect the
public. PREP Act coverage of countermeasures is critical to the
engagement with potential product sponsors to include those
countermeasures that would be used in a response, such as blood
products. Extension of the PREP Act declaration including covered
countermeasures for acute radiation exposure will be critical to United
States' preparedness for events involving ionizing radiation.
Unless otherwise noted, all statutory citations below are to the
U.S. Code.
Republished Declaration
Declaration, as Amended, for Public Readiness and Emergency
Preparedness Act Coverage for Acute Radiation Syndrome Medical
Countermeasures
This Declaration amends the January 1, 2016, Republished
Declaration under the PREP Act. To the extent any term of the prior
Declaration is inconsistent with any provision of this Republished
Declaration, the terms of this Republished Declaration are controlling.
I. Determination of Public Health Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d-6d(b)(1)
I have determined that there is a credible risk that an
unintentional radioactive release, a deliberate detonation of a nuclear
device, or other radiological or nuclear incident that could result in
population exposures to radiation and resulting acute radiation
syndrome and/or delayed effects of acute radiation exposure may in the
future constitute a public health emergency.
[[Page 80553]]
II. Factors Considered
42 U.S.C. 247d-6d(b)(6)
I have considered the desirability of encouraging the design,
development, clinical testing, or investigation, manufacture, labeling,
distribution, formulation, packaging, marketing, promotion, sale,
purchase, donation, dispensing, prescribing, administration, licensing,
and use of the Covered Countermeasures.
III. Recommended Activities
42 U.S.C. 247d-6d(b)(1)
I recommend, under the conditions stated in this Declaration, the
manufacture, testing, development, distribution, administration, or use
of the Covered Countermeasures.
IV. Liability Immunity
42 U.S.C. 247d-6d(a), 247d-6d(b)(1)
Liability immunity as prescribed in the PREP Act and conditions
stated in this Declaration is in effect for the Recommended Activities
described in section III.
V. Covered Persons
42 U.S.C. 247d-6d(i)(2), (3), (4), (6), (8)(A) and (B)
Covered Persons who are afforded liability immunity under this
Declaration are manufacturers, distributors, program planners,
``qualified persons,'' and their officials, agents, and employees, as
those terms are defined in the PREP Act, and the United States.
In addition, I have determined that the following additional
persons are qualified persons: (a) Any person authorized in accordance
with the public health and medical emergency response of the Authority
Having Jurisdiction, as described in section VII below, to prescribe,
administer, deliver, distribute or dispense the Covered
Countermeasures, and their officials, agents, employees, contractors
and volunteers, following a declaration of an emergency; (b) Any person
authorized to prescribe, administer, or dispense the Covered
Countermeasures or who is otherwise authorized to perform an activity
under an Emergency Use Authorization (EUA) in accordance with section
564 of the Federal Food, Drug, and Cosmetic (FD&C) Act, and; (c) Any
person authorized to prescribe, administer, or dispense Covered
Countermeasures in accordance with section 564A of the FD&C Act.
VI. Covered Countermeasures
42 U.S.C. 247d-6b(c)(1)(B), 42 U.S.C. 247d-6d(i)(1) and (7)
Covered Countermeasures are any antimicrobial (antibiotic,
antifungal, antiviral); any other drug; any biologic; or any diagnostic
or other device administered to identify, prevent or treat acute
radiation syndrome and its associated clinical manifestations, or
delayed effects of acute radiation exposure or adverse events from such
countermeasures.
Covered Countermeasures must be ``qualified pandemic or epidemic
products,'' or ``security countermeasures,'' or drugs, biological
products, or devices authorized for investigational or emergency use,
as those terms are defined in the PREP Act, the FD&C Act, and the PHS
Act.
VII. Limitations on Distribution
42 U.S.C. 247d-6d(a)(5) and (b)(2)(E)
I have determined that liability immunity is afforded to Covered
Persons only for Recommended Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts, cooperative agreements,
grants, other transactions, interagency agreements, memoranda of
understanding, or other Federal agreements, or activities directly
conducted by the Federal Government.
or
(b) Activities authorized in accordance with the public health and
medical response of the Authority Having Jurisdiction to prescribe,
administer, deliver, distribute or dispense the Covered Countermeasures
following a declaration of an emergency.
i. The Authority Having Jurisdiction means the public agency or its
delegate that has legal responsibility and authority for responding to
an incident, based on political or geographical (e.g., city, county,
tribal, state, or Federal boundary lines) or functional (e.g., law
enforcement, public health) range or sphere of authority.
ii. A declaration of emergency means any declaration by any
authorized local, regional, state, or Federal official of an emergency
specific to events that indicate an immediate need to administer and
use the Covered Countermeasures, with the exception of a Federal
Declaration in support of an EUA under section 564 of the FD&C Act
unless such Declaration specifies otherwise.
I have also determined that for governmental program planners only,
liability immunity is afforded only to the extent such program planners
obtain Covered Countermeasures through voluntary means, such as (1)
donation; (2) commercial sale; (3) deployment of Covered
Countermeasures from federal stockpiles; or (4) deployment of donated,
purchased, or otherwise voluntarily obtained Covered Countermeasures
from state, local, or private stockpiles.
VIII. Category of Disease, Health Condition, or Threat
42 U.S.C. 247d-6d(b)(2)(A)
The category of disease, health condition, or threat for which I
recommend the administration or use of the Covered Countermeasures is
acute radiation syndrome or delayed effects of acute radiation exposure
resulting from an unintentional radioactive release, a deliberate
detonation of a nuclear device, or other radiological or nuclear
incident.
IX. Administration of Covered Countermeasures
42 U.S.C. 247d-6d(a)(2)(B)
Administration of the Covered Countermeasure means physical
provision of the countermeasures to recipients, or activities and
decisions directly relating to public and private delivery,
distribution and dispensing of the countermeasures to recipients,
management and operation of countermeasure programs, or management and
operation of locations for purpose of distributing and dispensing
countermeasures.
X. Population
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(C)
The populations of individuals include any individual who uses or
is administered the Covered Countermeasures in accordance with this
Declaration.
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
to this population; liability immunity is afforded to program planners
and qualified persons when the countermeasure is used by or
administered to this population, or the program planner or qualified
person reasonably could have believed the recipient was in this
population.
XI. Geographic Area
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(D)
Liability immunity is afforded for the administration or use of a
Covered
[[Page 80554]]
Countermeasure without geographic limitation.
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
in these geographic areas; liability immunity is afforded to program
planners and qualified persons when the countermeasure is used by or
administered in these geographic areas, or the program planner or
qualified person reasonably could have believed the recipient was in
these geographic areas.
XII. Effective Time Period
42 U.S.C. 247d-6d(b)(2)(B)
Liability immunity for Covered Countermeasures obtained through
means of distribution other than in accordance with the public health
and medical response of the Authority Having Jurisdiction extends
through December 31, 2027.
Liability immunity for Covered Countermeasures administered and
used in accordance with the public health and medical response of the
Authority Having Jurisdiction begins with a Declaration and lasts
through (1) the final day the emergency Declaration is in effect or (2)
December 31, 2027, whichever occurs first.
XIII. Additional Time Period of Coverage
42 U.S.C. 247d-6d(b)(3)(B) and (C)
I have determined that an additional twelve (12) months of
liability protection is reasonable to allow for the manufacturer(s) to
arrange for disposition of the Covered Countermeasure, including return
of the Covered Countermeasures to the manufacturer, and for Covered
Persons to take other appropriate actions to limit the administration
or use of the Covered Countermeasures.
Covered Countermeasures obtained for the Strategic National
Stockpile (SNS) during the effective period of this Declaration for
Covered Countermeasures obtained through means of distribution other
than in accordance with the public health and medical response of the
Authority Having Jurisdiction are covered through the date of
administration or use pursuant to a distribution or release from the
SNS.
XIV. Countermeasures Injury Compensation Program
42 U.S.C. 247d-6e
The PREP Act authorizes the Countermeasures Injury Compensation
Program (CICP) to provide benefits to certain individuals or estates of
individuals who sustain a serious physical covered injury as the direct
result of the administration or use of the Covered Countermeasures and/
or benefits to certain survivors of individuals who die as a direct
result of the administration or use of the Covered Countermeasures. The
causal connection between the countermeasure and the serious physical
injury must be supported by compelling, reliable, valid, medical, and
scientific evidence in order for the individual to be considered for
compensation. The CICP is administered by the Health Resources and
Services Administration, within the Department of Health and Human
Services. Information about the CICP is available at the toll-free
number 1-855-266-2427 or https://www.hrsa.gov/cicp/.
XV. Amendments
42 U.S.C. 247d-6d(b)(4)
The October 10, 2008, Declaration Under the PREP Act for Acute
Radiation Syndrome Medical Countermeasures was first published on
October 17, 2008, and amended and republished on January 1, 2016. This
is the second amendment to the Declaration.
Further amendments to this Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d-6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022-28437 Filed 12-29-22; 8:45 am]
BILLING CODE 4150-37-P